These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 29682695)

  • 1. Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics.
    Dash RP; Babu RJ; Srinivas NR
    Clin Pharmacokinet; 2018 Nov; 57(11):1385-1398. PubMed ID: 29682695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
    Jaiswal MK
    Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Riluzole 5 mg/mL oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis.
    Dyer AM; Smith A
    Drug Des Devel Ther; 2017; 11():59-64. PubMed ID: 28053507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System.
    Vu M; Tortorice K; Zacher J; Dong D; Hur K; Zhang R; Good CB; Glassman PA; Cunningham FE
    JAMA Netw Open; 2020 Oct; 3(10):e2014645. PubMed ID: 33017028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Edaravone for the treatment of amyotrophic lateral sclerosis.
    Yoshino H
    Expert Rev Neurother; 2019 Mar; 19(3):185-193. PubMed ID: 30810406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease-modifying treatment of amyotrophic lateral sclerosis.
    Schultz J
    Am J Manag Care; 2018 Aug; 24(15 Suppl):S327-S335. PubMed ID: 30207671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Edaravone - Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis.
    Pattee GL; Genge A; Couratier P; Lunetta C; Sobue G; Aoki M; Yoshino H; Jackson CE; Wymer J; Salah A; Nelson S
    Expert Rev Neurother; 2023; 23(10):859-866. PubMed ID: 37646130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
    Bhandari R; Kuhad A; Kuhad A
    Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Adamantane-Containing Edaravone Conjugates as Potential Neuroprotective Agents for ALS Treatments.
    Lapshina MA; Shevtsova EF; Grigoriev VV; Aksinenko AY; Ustyugov AA; Steinberg DA; Maleev GV; Dubrovskaya ES; Goreva TV; Epishina TA; Zamoyski VL; Makhaeva GF; Fisenko VP; Veselov IM; Vinogradova DV; Bachurin SO
    Molecules; 2023 Nov; 28(22):. PubMed ID: 38005288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drugs for Amyotrophic Lateral Sclerosis].
    Ogino M
    Brain Nerve; 2023 May; 75(5):503-506. PubMed ID: 37194520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis.
    Bruno R; Vivier N; Montay G; Le Liboux A; Powe LK; Delumeau JC; Rhodes GR
    Clin Pharmacol Ther; 1997 Nov; 62(5):518-26. PubMed ID: 9390108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Edaravone Oral Suspension: A Neuroprotective Agent to Treat Amyotrophic Lateral Sclerosis.
    Singh P; Belliveau P; Towle J; Neculau AE; Dima L
    Am J Ther; 2024 May-Jun 01; 31(3):e258-e267. PubMed ID: 38691665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.
    Witzel S; Maier A; Steinbach R; Grosskreutz J; Koch JC; Sarikidi A; Petri S; Günther R; Wolf J; Hermann A; Prudlo J; Cordts I; Lingor P; Löscher WN; Kohl Z; Hagenacker T; Ruckes C; Koch B; Spittel S; Günther K; Michels S; Dorst J; Meyer T; Ludolph AC;
    JAMA Neurol; 2022 Feb; 79(2):121-130. PubMed ID: 35006266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis.
    Shimizu H; Nishimura Y; Shiide Y; Akimoto M; Yashiro M; Ueda M; Hirai M; Yoshino H; Mizutani T; Kanai K; Kano O; Kimura H; Sekino H; Ito K
    Clin Ther; 2023 Dec; 45(12):1251-1258. PubMed ID: 37953075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis.
    Noto Y; Shibuya K; Vucic S; Kiernan MC
    Expert Rev Neurother; 2016 Oct; 16(10):1147-54. PubMed ID: 27314534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS).
    Bireley JD; Morren JA
    Expert Opin Investig Drugs; 2023; 32(8):677-683. PubMed ID: 37642362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain and plasma riluzole pharmacokinetics: effect of minocycline combination.
    Milane A; Tortolano L; Fernandez C; Bensimon G; Meininger V; Farinotti R
    J Pharm Pharm Sci; 2009; 12(2):209-17. PubMed ID: 19732498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Riluzole: a new agent for amyotrophic lateral sclerosis.
    Wagner ML; Landis BE
    Ann Pharmacother; 1997 Jun; 31(6):738-44. PubMed ID: 9184716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Riluzole, neuroprotection and amyotrophic lateral sclerosis.
    Cheah BC; Vucic S; Krishnan AV; Kiernan MC
    Curr Med Chem; 2010; 17(18):1942-199. PubMed ID: 20377511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of riluzole: evidence for glucuronidation as a major metabolic pathway not associated with UGT1A1 genotype.
    van Kan HJ; van den Berg LH; Groeneveld GJ; van der Straaten RJ; van Vught PW; Lie-A-Huen L; Guchelaar HJ
    Biopharm Drug Dispos; 2008 Apr; 29(3):139-44. PubMed ID: 18098330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.